| Full text | |
| Author(s): |
Tamura, Rodrigo Esaki
[1]
;
de Luna, Igor Vieira
[1]
;
Lana, Marlous Gomes
[1]
;
Strauss, Bryan E.
[1]
Total Authors: 4
|
| Affiliation: | [1] Univ Sao Paulo, Hosp Clin HCFMUSP, ICESP, Lab Vetores Virais, Ctr Invest Translac Oncol, Fac, Sao Paulo, SP - Brazil
Total Affiliations: 1
|
| Document type: | Review article |
| Source: | Clinics; v. 73, n. 1 2018. |
| Web of Science Citations: | 2 |
| Abstract | |
Gene therapy has been evaluated for the treatment of prostate cancer and includes the application of adenoviral vectors encoding a suicide gene or oncolytic adenoviruses that may be armed with a functional transgene. In parallel, versions of adenoviral vector expressing the p53 gene (Ad-p53) have been tested as treatments for head and neck squamous cell carcinoma and non-small cell lung cancer. Although Ad-p53 gene therapy has yielded some interesting results when applied to prostate cancer, it has not been widely explored, perhaps due to current limitations of the approach. To achieve better functionality, improvements in the gene transfer system and the therapeutic regimen may be required. We have developed adenoviral vectors whose transgene expression is controlled by a p53-responsive promoter, which creates a positive feedback mechanism when used to drive the expression of p53. Together with improvements that permit efficient transduction, this new approach was more effective than the use of traditional versions of Ad-p53 in killing prostate cancer cell lines and inhibiting tumor progression. Even so, gene therapy is not expected to replace traditional chemotherapy but should complement the standard of care. In fact, chemotherapy has been shown to assist in viral transduction and transgene expression. The cooperation between gene therapy and chemotherapy is expected to effectively kill tumor cells while permitting the use of reduced chemotherapy drug concentrations and, thus, lowering side effects. Therefore, the combination of gene therapy and chemotherapy may prove essential for the success of both approaches. (AU) | |
| FAPESP's process: | 11/21256-8 - Combination of chemotherapy and adenoviral vectors expressing p53 for the therapy of prostate cancer |
| Grantee: | Rodrigo Esaki Tamura |
| Support Opportunities: | Scholarships in Brazil - Post-Doctoral |
| FAPESP's process: | 15/26580-9 - Cancer gene therapy: strategic positioning for translational studies |
| Grantee: | Bryan Eric Strauss |
| Support Opportunities: | Research Projects - Thematic Grants |
| FAPESP's process: | 12/05066-7 - Use of shRNA anti-hexon e anti-IVa2 during the production of adeno-associated virus as a strategy for eliminating helper adenovirus: Proof of principle |
| Grantee: | Marlous Vinícius Gomes Lana |
| Support Opportunities: | Scholarships in Brazil - Master |
| FAPESP's process: | 16/18197-3 - Investigation of the direct and paracrine angiogenic effects after gene transfer mediated by adenoviral vectors carrying the Interferon-beta in murine melanoma |
| Grantee: | Igor de Luna Vieira |
| Support Opportunities: | Scholarships in Brazil - Doctorate |
| FAPESP's process: | 13/25167-5 - P19Arf and interferon-beta gene transfer: delineating the importance of their combination in mouse models of cancer gene therapy |
| Grantee: | Bryan Eric Strauss |
| Support Opportunities: | Regular Research Grants |